Souhaitez-vous accéder aux communiqués récents ?

Media Release Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a...

Company Announcement In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate (ARR) over teriflunomide in patients with relapsing forms of multiple...

Company Announcement DARZALEX® approved in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem...

Media Release Copenhagen, Denmark, August 21, 2019 Genmab A/S (Nasdaq: GMAB) announced today that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung...

Company Announcement Copenhagen, Denmark; August 20, 2019 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 21,811 shares as a consequence of the exercise of employee warrants. The...

Media Release Copenhagen, Denmark, August 19, 2019 Thirteen Janssen-sponsored abstracts featuring daratumumab selected for presentation at the 17th International Myeloma Workshop (IMF) Genmab A/S...

August 14, 2019; Copenhagen, Denmark; Interim Report for the First Half of 2019 Highlights Registration statement filed with the U.S. Securities and Exchange Commission for the...

Company Announcement Genmab A/S has today completed the closing of the exercise in full by the underwriters of their over-allotment option in connection with its initial public offering of American...

Company Announcement Genmab A/S has today completed its initial public offering of American Depositary Shares in the United States and registered a capital increase of 2,850,000 ordinary shares in...

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 19, 2019 – Genmab A/S (CSE: GEN, Nasdaq: GMAB) announces under reference to Section 30 of the Danish...